Cogent Biosciences Inc
Change company Symbol lookup
Select an option...
COGT Cogent Biosciences Inc
GPGC Global PoleTrusion Group Corp
APN Apeiron Capital Investment Corp
TSLA Tesla Inc
TOL Toll Brothers Inc
LHAA Lerer Hippeau Acquisition Corp
PSUD Petrosun Inc
ADIL Adial Pharmaceuticals Inc
CGNT Cognyte Software Ltd
XP XP Inc
Go

Health Care : Biotechnology | Small Cap Value
Company profile

Cogent Biosciences, Inc. is a biotechnology company that is focused on developing precision therapies for genetically defined diseases. The Company’s most advanced clinical program, bezuclastinib (CGT9486), is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. In addition to bezuclastinib, the Company is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases. The Company has initiated APEX, a Phase II clinical study of bezuclastinib in patients with AdvSM. APEX is an open-label, global, multicenter study evaluating the safety, efficacy, pharmacokinetic, and pharmacodynamic profiles of bezuclastinib. It also initiated Peak, a randomized, open-label, global Phase III clinical trial.

Closing Price
$14.02
Day's Change
-0.87 (-5.84%)
Bid
--
Ask
--
B/A Size
--
Day's High
14.72
Day's Low
13.77
Volume
(Light)
Volume:
780,304

10-day average volume:
1,431,147
780,304

Company Profile

Cogent Biosciences, Inc. is a biotechnology company that is focused on developing precision therapies for genetically defined diseases. The Company’s most advanced clinical program, bezuclastinib (CGT9486), is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. In addition to bezuclastinib, the Company is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases. The Company has initiated APEX, a Phase II clinical study of bezuclastinib in patients with AdvSM. APEX is an open-label, global, multicenter study evaluating the safety, efficacy, pharmacokinetic, and pharmacodynamic profiles of bezuclastinib. It also initiated Peak, a randomized, open-label, global Phase III clinical trial.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
--
Price/Book (MRQ)
3.71x
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

No historic growth available.

Short Interest

August 2022
Current Month
3.2M
Previous Month
4.6M
Percent of Float
5.14%
Days to Cover
2.0273 Days

Share Information

COGT is in a share class of common stock
Float
65.8M
Shares Outstanding
65.8M
Institutions Holding Shares
149
115.75%

Financial Statements

Balance sheet

Values displayed are in thousands.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

  • Peter Harwin
  • Andrew R. RobbinsPres.
  • John L. GreenCFO
  • John RobinsonCSO
  • Jessica SachsOther

Address

Insider Trading

During the most recent quarter, 1M shares were bought in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.